Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Nathan Kuemmerle

Psychiatry West Hollywood, CA Medical Doctor

NPI 1821030560 CMS profile 443786

8235 Santa Monica Blvd, Suite #303, West Hollywood, CA 90046

Open in the dashboard

General payments

$22,124

905 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Nathan Kuemmerle of West Hollywood, CA is reported in the CMS Open Payments database as having received $22,124 across 905 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $110 1
2022 General $5,196 197
2021 General $6,952 320
2020 General $4,352 200
2019 General $5,515 187

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Kuemmerle
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Nathan Kuemmerle were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Nathan Kuemmerle Psychiatry median Middle half National median
2019 $5,515 $184 $59–$605 $163
2020 $4,352 $119 $36–$372 $114
2021 $6,952 $143 $43–$576 $132
2022 $5,196 $153 $50–$590 $149
2023 $110 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $4,844 170 payments
  2. Neurocrine Biosciences, Inc. $2,783 82 payments
  3. Alkermes, Inc. $2,727 88 payments
  4. Otsuka America Pharmaceutical, Inc. $2,051 101 payments
  5. Sunovion Pharmaceuticals Inc. $1,818 61 payments
  6. Vanda Pharmaceuticals Inc. $1,468 65 payments
  7. Teva Pharmaceuticals USA, Inc. $1,338 55 payments
  8. Allergan Inc. $899 40 payments
  9. ITI, Inc. $850 26 payments
  10. AbbVie, Inc. $703 50 payments
  11. Other $2,642 167 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $21,897 899 payments
  2. Education $227 6 payments
Products named General payments · program years 2019–2023
  1. INVEGA SUSTENNA $3,752 151 payments
  2. SPRAVATO $2,932 103 payments
  3. ARISTADA INITIO $2,145 77 payments
  4. ARISTADA Cns $2,145 77 payments
  5. ARISTADA Cns $2,145 77 payments
  6. LATUDA $1,806 60 payments
  7. INVEGA TRINZA $1,746 70 payments
  8. ARISTADA Cns $1,656 54 payments
  9. ARISTADA Cns $1,656 54 payments
  10. FANAPT $1,468 65 payments
  11. Other $15,830 671 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

905 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record